

**Stephen L. CHAN, MBBS (HKU), MD (CUHK), MRCP (UK), FHKCP, FHKAM
(Medicine), FRCP (Edin., Lond.)**

Dr. Stephen Chan is currently the clinical Associate Professor at the Department of Clinical Oncology, The Chinese University of Hong Kong. He is a medical oncologist with research interest focusing on clinical development of novel treatment for liver and pancreatobiliary cancers. His research has earned him the Young investigator award and Gold medal on dissertation awarded by the Hong Kong College of Physicians.

Dr. Chan is active internationally. Apart from being the key investigator of multiple international clinical trials on HCC, he is currently the international member of the NCI Hepatobiliary Task Force of the Gastrointestinal Steering Committee in United States. He serves in the editorial board of multiple journals including the liver international and The International Journal of Biological Markers. Dr. Chan published more than 100 papers in peer-review journals with some in high-impact journals including the Journal of Clinical Oncology and the Lancet.

Professional Qualification:

Bachelor of Medicine and Bachelor of Surgery (The University of Hong Kong) (2000)

Membership of the Royal College of Physicians (United Kingdom) (2003)

Fellowship of Hong Kong College of Physicians (2007)

Fellowship of Hong Kong Academy of Medicine (Medicine) (2007)

Fellowship of Royal College of Physician (Edinburgh) (2014)

Fellowship of Royal College of Physician (London) (2016)

Doctor of Medicine (The Chinese University of Hong Kong) (2018)

Employment History:

Resident, Department of Clinical Oncology, Prince of Wales Hospital (Jul 2001 - Jun 2007)

Resident Specialist, Department of Clinical Oncology, Prince of Wales Hospital (Jul 2007 - Mar 2008)

Assistant (Clinical) Professor, Department of Clinical Oncology, The Chinese University of Hong Kong (Mar 2008 - Feb 2014)

Associate (Clinical) Professor, Department of Clinical Oncology, The Chinese University of Hong Kong (Mar 2014 - Present)

Selected Publications (in descending order of impact factor):

1. Abou-Alfa, G.K., Meyer, T., Cheng, A.L., El-Khoueiry, A.B., Rimassa, L., Ryoo, B.Y., Cicin, I., Merle, P., Chen, Y., Park, J.W., Blanc, J.F., Bolondi, L., Klumpen, H.J., **Chan, S.L.**, Zagonel, V., Pressiani, T., Ryu, M.H., Venook, A.P., Hessel, C., Borgman-Hagey, A.E., Schwab, G., & Kelley, R.K. (2018). Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. *N Engl J Med*, 379(1), 54-63. PMID: 29972759 (Impact factor: 79.258)
2. Zhu, A.X., Finn, R.S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., Sarker, D., Verset, G., **Chan, S.L.**, Knox, J., Daniele, B., Webber, A.L., Ebbinghaus, S.W., Ma, J., Siegel, A.B., Cheng, A.L., Kudo, M., & KEYNOTE-224 investigators. (2018). Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. *Lancet Oncol*, 19(7), 940-952. PMID: 29875066 (Impact factor: 36.418)
3. **Chan, S.L.**, Wong, V.W., Qin, S., & Chan, H.L. (2016). Infection and Cancer: the case of hepatitis B. *J Clin Oncol*, 34,83-90. PMID: 26578611 (Impact factor: 26.303)
4. Johnson, P.J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H.L., O'Beirne, J., Fox, R., Skowronska, A., Palmer, D., Yeo, W., Mo, F., Lai, P., Inarrairaegui, M., **Chan, S.L.**, Sangro, B., Miksad, R., Tada, T., Kumada, T., & Toyoda, H. (2015). Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—The ALBI Grade. *J Clin Oncol*, 33(6), 550-558. PMID: 25512453 (Impact factor: 26.303)
5. Yeo, W., Chung, H.C., **Chan, S.L.**, Wang, L.Z., Lim, R., Picus, J., Boyer, M., Mo, F.K., Koh, J., Rha, S.Y., Hui, E.P., Jeung, H.C., Roh, J.K., Yu, S.C., To, K.F., Tao, Q., Ma, B.B., Chan, A.W., Tong, J.H., Erlichman, C., Chan, A.T., & Goh, B.C. (2012). Epigenetic therapy using Belinostat for patients with unresectable hepatocellular carcinoma: A multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. *J Clin Oncol*, 30(27), 3361-3367. PMID: 22915658 (Impact factor: 26.303)
6. Wong, V.W.*, **Chan, S.L.***, Mo, F., Chan, T.C., Loong, H.H., Wong, G.L., Lui, Y.Y., Chan, A.T., Sung, J.J., Yeo, W., Chan, H.L., & Mok, T.S. (2010). Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. (*equal contribution). *J Clin Oncol*, 28(10), 1660-1665. PMID: 20194845 (Impact factor: 26.303)
7. **Chan, S.L.**, Mo, F., Johnson, P.J., Hui, E.P., Ma, B.B., Ho, W.M., Lam, K.C., Chan, A.T., Mok, T.S., & Yeo, W. (2009). New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiological response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. *J Clin Oncol* 27:446-452. (Impact factor: 26.303)
8. Li, C.H., To, K.F., Tong, J.H., Xiao, Z., Xia, T., Lai, P.B., Chow, S.C., Zhu, Y.X., **Chan, S.L.**, Marquez, V.E., & Chen, Y. (2013). Enhancer of zeste homolog 2 silences mir-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin. *Gastroenterology*, 144(5), 1086-1097. PMID: 23395645 (Impact factor: 20.773)
9. Cheng, A.L., Thongprasert, S., Lim, H.Y., Sukeepaisarnjaroen, W., Yang, T.S., Wu, C.C., Chao, Y., **Chan, S.L.**, Kudo, M., Ikeda, M., Kang, Y.K., Pan, H., Numata, K., Han, G., Balsara, B., Zhang, Y., Rodriguez, A.M., Zhang, Y., Wang, Y., & Poon, R.T. (2016). Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. *Hepatology*, 64(3), 774-784. PMID: 27082062 (Impact factor: 14.079)
10. Chan, A.W., Leung, H.H., Chong, C.C., & **Chan, S.L.** (2017). Validating the ALBI grade: Its current and future use in HCC prognostication. *J Hepatol*, 66(3), 661-663. PMID: 27890792 (Impact factor: 14.911)